MaxCyte(MXCT.US)

Last Updated 19:00:00 ET
longbridge loading

River Global Investors Discloses Investment in MaxCyte with 6.1% Stake

TradingView·
US
MXCT
-1.89%
TradingView·
US
MXCT
-1.89%

MaxCyte | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 9.651 M

Earnings Watch·
US
MXCT
-1.89%
Earnings Watch·
US
MXCT
-1.89%

12 Health Care Stocks Moving In Wednesday's Intraday Session

benzinga_article·
US
RVPH
-1.20%
US
REPL
-6.19%
US
MXCT
-1.89%
benzinga_article·
US
RVPH
-1.20%
US
REPL
-6.19%
US
MXCT
-1.89%

MaxCyte (MXCT) Gets a Buy from Stifel Nicolaus

Tip Ranks·
US
MXCT
-1.89%
Tip Ranks·
US
MXCT
-1.89%

Cisco, Alibaba And 3 Stocks To Watch Heading Into Wednesday

benzinga_article·
US
CSCO
-2.94%
US
BABA
+1.79%
US
MXCT
-1.89%
benzinga_article·
US
CSCO
-2.94%
US
BABA
+1.79%
US
MXCT
-1.89%

MaxCyte shares are trading higher after the company reported better-than-expected Q1 financial results.

benzinga_article·
US
MXCT
-1.89%
benzinga_article·
US
MXCT
-1.89%

Craig-Hallum Remains a Buy on MaxCyte (MXCT)

Tip Ranks·
US
MXCT
-1.89%
Tip Ranks·
US
MXCT
-1.89%

MaxCyte | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 9.651 M

Earnings Watch·
US
MXCT
-1.89%
Earnings Watch·
US
MXCT
-1.89%

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Caplyta for Adults with Schizophrenia]]>

Pharmexec·
US
JNJ
+0.47%
US
LLY
+3.37%
US
MXCT
-1.89%
Pharmexec·
US
JNJ
+0.47%
US
LLY
+3.37%
US
MXCT
-1.89%
© 2026 Longbridge｜Disclaimer